ID   K562 Dox #8 NIL
AC   CVCL_E6IF
SY   K562-Dox #8 NIL
RX   PubMed=27536777;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_28748; Doxorubicin (Adriablastin; Adriamycin).
CC   Selected for resistance to: ChEBI; CHEBI_52172; Nilotinib (AMN107; Tasigna).
CC   Sequence variation: Gene fusion; HGNC; HGNC:76; ABL1 + HGNC; HGNC:1014; BCR; Name(s)=BCR-ABL1, BCR-ABL; Note=BCR exon 14 fused to ABL1 exon 2 (b3a2 transcript) (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_E6HY ! K562 Dox
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=27536777; DOI=10.1371/journal.pone.0161470; PMCID=PMC4990177;
RA   Eadie L.N., Hughes T.P., White D.L.;
RT   "ABCB1 overexpression is a key initiator of resistance to tyrosine
RT   kinase inhibitors in CML cell lines.";
RL   PLoS ONE 11:e0161470.1-e0161470.18(2016).
//